Journal of Research Administration
Society of Research Administrators International

AN EXAMINATION OF FINANCIAL PERFORMANCE BEFORE AND AFTER MERGERS: A CASE STUDY OF SELECTED INDIAN PHARMACEUTICAL COMPANIES

K. Naveen Kumar
Research Scholar, Rabindranath Tagore University, Bhopal
ORCID : 0000-0002-9764-6048

Dr. Manali Upadhyay
Assistant Professor, Department Of Commerce, Rabindranath Tagore University, Bhopal

Prof. Dr. Deepti Maheshwari
Rabindranath Tagore University, Bhopal

Abstract
Mergers and acquisitions (M&A) are strategic initiatives pursued by companies to enhance their market position, achieve economies of scale, and foster growth. The Indian pharmaceutical sector has witnessed a significant number of mergers in recent years, prompting an in-depth analysis of the financial performance of companies involved. The purpose of this research is to use quantitative analysis and comparative assessment techniques to evaluate the financial performance of chosen firms in the Indian pharmaceutical industry before and after a merger took place.The research methodology involves a comprehensive review of financial statements, balance sheets, and other relevant financial documents from the pre-merger and post-merger periods. Furthermore, qualitative factors such as management effectiveness, market share, and competitive advantage are also considered to provide a holistic understanding of the mergers' implications.The findings of this study contribute valuable insights to the existing literature on mergers and acquisitions in the pharmaceutical industry. This study aids stakeholders, such as investors, legislators, and industry experts, by comparing the pre- and post-merger financial performance of chosen organisations. Additionally, the study sheds light on the factors that influence the success of mergers in the Indian pharmaceutical sector, offering practical recommendations for companies contemplating similar strategic moves in the future.This research is conducted with utmost integrity, ensuring that all sources are properly cited and referenced to maintain academic rigor and prevent plagiarism. The conclusions of this research have the potential to lead future M&A strategies in the pharmaceutical sector, supporting sustainable growth and development within the business.

Keywords: Mergers and Acquisitions, Financial Performance, Indian Pharmaceutical Sector, Financial Ratios, Competitive Advantage, Management Effectiveness, Market Share.

Introduction

Because of its central position at the crossroads of innovation, technology, and healthcare, India's pharmaceutical industry is crucial to the country's economic development and international status. Companies' strategies to increase their competitive edge, broaden their market presence, and encourage innovation have led to a rise in M&A activity in recent years. Mergers, when executed strategically, have the potential to create synergies, streamline operations, and improve overall financial performance. Understanding the impact of these mergers on the financial health of the involved companies is of paramount importance to stakeholders, investors, and industry analysts. By delving into the financial intricacies before and after these strategic alliances, this research endeavors to unravel patterns, discern trends, and offer valuable insights into the effectiveness of these mergers. In the face of globalization, regulatory changes, and evolving consumer demands, deciphering the dynamics of M&A activities becomes instrumental for companies aiming to thrive in this competitive landscape. The Indian pharmaceutical sector, a significant contributor to the country's economy, has witnessed a surge in merger activities in recent years. Researchers, investors, and business professionals have taken a strong interest in understanding the effects of this trend on the bottom lines of the firms involved.Competition is fierce, regulatory environments are shifting quickly, and consumer preferences are always shifting in India's pharmaceutical business. In response to these challenges, companies often explore mergers as a means to strengthen their market presence, optimize resources, and gain strategic advantages. While the motivations behind these mergers are multifaceted, assessing their impact on the financial health of the involved entities is crucial for understanding their long-term sustainability and success. By conducting a comprehensive analysis, this research aims to uncover patterns, trends, and key indicators that can offer valuable insights into the effectiveness of mergers as strategic tools in the industry. Understanding the factors that contribute to successful mergers and their subsequent impact on financial performance is essential for companies, investors, and policymakers alike.

Review of Literature

Researchers such as Kapoor and Jain (2017) have delved into the motivations driving M&A activities in the pharmaceutical sector. They emphasize the strategic objectives behind mergers, including access to new markets, diversification of product portfolios, and consolidation of research and development efforts. Additionally, studies by Reddy and Patnaik (2016) have analyzed the strategies employed by pharmaceutical companies during M&A transactions, emphasizing the importance of synergy realization, integration planning, and effective post-merger integration processes. Several scholars have examined the financial metrics used to evaluate the success of M&A transactions. Ratios such margins, and liquidity ratios have been widely utilized (Singh & Pandey, 2018). These studies highlight the significance of analyzing both short-term and long-term financial indicators to assess the impact of mergers on profitability, liquidity, and efficiency.

Research conducted by Agarwal and Raman (2019) has explored the challenges faced by companies during the post-merger integration phase. Integration issues such as cultural differences, organizational restructuring, and technology assimilation have been identified as critical factors influencing the overall success of mergers. Understanding and effectively managing these challenges are pivotal to ensuring a smooth transition and maximizing the synergistic benefits of M&A activities.

Studies by Dr.Naveen Prasadula (2021) have investigated the market reaction to M&A announcements in the pharmaceutical sector. These studies analyze stock price movements, trading volumes, and investor sentiments surrounding merger announcements, providing insights into market perceptions and investor expectations. Understanding these reactions is essential for companies and investors alike, as they offer valuable cues about market sentiment and confidence in the merger's success. By synthesizing insights from previous research, this study aims to build upon the existing knowledge, employing a rigorous analytical framework to assess the financial impact of selected mergers in the industry. The collective wisdom from prior studies underscores the complexity of M&A transactions and emphasizes the need for a nuanced analysis that considers various financial and non-financial factors.

Significance of the Study

This research holds significant implications for various stakeholders. For companies contemplating mergers, the findings can provide valuable insights into the potential benefits and challenges associated with such strategic decisions. Investors can use the results to make informed investment choices, considering the financial stability and growth prospects of merged entities. Additionally, policymakers and regulatory bodies can benefit from a deeper understanding of the industry dynamics, aiding in the formulation of policies that promote responsible and sustainable M&A activities. The study of pre and post-merger financial performance has been a subject of substantial interest among researchers and scholars in the field of finance and strategic management. Previous studies have explored various aspects of mergers and acquisitions (M&A), shedding light on the factors influencing M&A activities, their impact on financial performance, and the strategies employed by companies to maximize the benefits of such transactions. In the context of the Indian pharmaceutical sector, several scholars have contributed to the understanding of M&A dynamics and their consequences.

Objectives

1. To Evaluate Pre-Merger Financial Performance: This study intends to analyze the financial statements of selected pharmaceutical companies before their respective mergers. By examining key financial metrics and ratios, the research aims to establish a baseline for comparison with post-merger performance.
2. To Assess Post-Merger Financial Performance: The research will delve into the financial performance of the same companies following the merger events. By employing similar financial metrics, the study seeks to identify changes in the companies' financial health, profitability, and operational efficiency post-merger.
3. To Identify Key Success Factors: These factors may include improved economies of scale, enhanced research and development capabilities, expanded market reach, and optimized supply chain management.

Research and Methodology

This study adopts a longitudinal and comparative research design to assess A quantitative approach is employed to analyze financial data, allowing for systematic comparison and trend analysis.

A purposive sampling method is utilized to select companies that have undergone mergers within the specified timeframe. Criteria for selection include mergers completed within the last five years, publicly available financial data, and representativeness of different segments within the pharmaceutical industry (e.g., generics, research-oriented, and regional players).

Financial data is collected from company reports, audited financial statements, and relevant regulatory filings. Pre-merger financial data covers a period of three years before the merger, while post-merger data spans a similar duration after the completion of the merger.

These ratios serve as key indicators of financial performance and are essential for comparative analysis.

Quantitative data is analyzed using statistical techniques such as paired t-tests and trend analysis. Paired t-tests are employed to assess Trend analysis involves examining the direction and magnitude of changes in financial ratios over time, providing insights into the overall trajectory of financial performance post-merger.

In addition to quantitative analysis, qualitative factors such as management effectiveness, market share dynamics, and competitive advantage are qualitatively assessed through industry reports, expert interviews, and company presentations. “Qualitative insights offer a holistic understanding of the mergers' impact on non-financial aspects of company performance.

RESEARCH HYPOTHESIS:-

H0: Merger and Acquisition have no impact onoperating performance.

H1: Merger and Acquisition have positive impacton operating performances.

H0: Merger and Acquisition have no impact onshareholder’s wealth.

H1: Merger and Acquisition have positive impacton shareholder’s wealth.

METHODOLOGY:-

Data are collected from various sources for thisstudy .

- The required data are taken through published financial and annual reports of the selected Company website.
- For the purpose of study we taken 7 years data, 3 years for pre-merger period and 3years for post-merger period.2014 is taken asbase year as it the year of merger.
- The various financial techniques such as ratio analysis, trend analysis is being used. The profiles of both acquiring and acquired firms at the time of merger/acquisition have been collected from annual reports,newspaper clippings, websites etc.

S. N.	Bidder firm	Target firm	Year
Merger 1	Sun ***pharmaceuticalLtd.***	Ranbaxy ***pharmaceuticalLtd.***	2014
Merger 2	Torrent ***pharmaceuticalLtd.***	Elder ***pharmaceutical Ltd.***	2014

ANALYSIS AND INTERPRETATION:-

For my research study I have taken Return on capital employed, Gross Profit Margin, Total debt- equity ratios Operating Profit Margin, Net profit margin, for evaluate the Operating performance of company and Earning per share, Return on net worth and Earning Retention Ratio for evaluate the Shareholder's Wealth of the company.

Table 1: Analysis of financial ratios of SunPharma for Operating Performance

Sun Pharma		Mean	S.D	t-value	p-value
Operating Profit Margin	Pre	31.00	17.25	0.105	0.9
	Post	29.84	2.06		
Gross ProfitMargin	Pre	25.83	2.06	-7.937	0.016
	Post	46.57	2.80		
Net ProfitMargin	Pre	31.00	17.23	1.277	0.33
	Post	18.24	3.47		
Return onCapital employed	Pre	23.60	3.20	1.359	0.30
	Post	20.55	1.52		
Debt-equityRatio	Pre	0.023	0.15	-16.059	0.004
	Post	0.256	0.04		

(Source:-Compilation from financial state of dataretrieves Moneycontrol.com by SPSS)

It will show that the mean value of the operating profit margin is decreased from 31% to 29.84% post merger period with t-value 0.105 which is statistically significant at 0.05% significance level as the critical p-value is 0.9 which is above 0.05,so it is insignificant. Same as the mean value of net profit margin and ROCE has significantly decreased from 31% to 18.24% and 23.60% to 20.55% during post merger period as compared to pre-merger period with t-value of 1.277,1.359 respectively and P value of 0.30 and

0.33 which is above than 0.05%, so it is insignificant. The decrease in all these three ratios signifies that the operating performance has significantly gone down in post-merger. Consequently H0 (Null Hypotheses) is acceptedwhich shows that there are no significant differences between pre and post-merger operatingperformance in terms of operating profit margin, net profit margin and ROCE of Sun Pharma . On the other hand, the mean value of Gross profit margin and Debt-Equity

Ratios has significantlyincreased to 25.83% to 46.57% and 0.02% to 0.25% during post merger period as compared to pre-merger period with t-value of -7.937 and - 16.059 respectively and in the other hand P value of 0.016 and 0.004 which is less than 0.05%, so itis significant.So, H0 (null hypotheses) is rejected leading to the acceptance of H1 (alternate hypotheses).So it will show that no significant impact between pre and post-merger period . In the above analysis shows that after merger the Operating Performance will go down in three ratiosbut on the other hand Debt-Equity ratio and gross profit ratio will increase which shows that the of Ranboxy is have a mixed impact on Sun pharma with regard to operating performance of the bidder firm.

To evaluate the financial difference we can use financial ratios before and after merger, paired t-test use with the help of SPSS.
The above analysis would show in table 1. The Net profit margin, Operating profit margin, ROCE ratio the p-value is more than 0.05 percent, it can be find that there is no significant difference in these ratios before and after merger. For Gross Profit Margin and Debt-Equity Ratios the p value was less than 0.05 percent so it can be ascertained that there is a difference before and after merger. So the Operating Performance will go down during pre and post-merger period but the debt-Equity will more stronger in after merger period.

Table 2:-Analysis of financial ratios of Sun Pharm. for Shareholder's wealth

Sun Pharma		Mean	S.D	t-value	p-value
Return onNet worth	Pre	23.50	2.36	3.413	0.076
	Post	16.84	2.72		
EarningsPer Share(EPS)	Pre	53.53	11.87	-4.464	0.04
	Post	89.14	6.24		
Earning RetentionRatio	Pre	39.47	4.89	-24.085	0.002
	Post	89.15	6.25		

(Source:-Compilation from financial state of data retrieves Moneycontrol.com by SPSS)

Shareholder's wealth of pre and post-merger periodwill evaluated on the basis of key ratios. Here Return on Net worth, Earnings Per Share (EPS), Earning Retention Ratio are indicates Performance Indicators.

For my study, I have used Paired't' test for dataanalysis with the help of SPSS Packages.

It would be evaluated that the mean value of the Return on net worth ratios has decreased from 23.50% to 16.84% post merger with t-value 3.413 which is statistically insignificant at 0.05% significance level as the critical p-value is 0. 0.076 which is above 0.05, so it is insignificant. The mean value of EPS and Earning Retention Ratio has significantly increased from 53.53% to 89.14%and 39.47% to 89.15% during post merger period as compared to pre-merger period with t-value of - 4.464 and -24.085 and P value of 0.04,0.002 respectively. The increase in all these two ratios signifies that the shareholder's wealth has significantly gone up in post-merger. ConsequentlyH1 is accepted which will show that there are significant differences between pre and post-merger shareholder's wealth in terms of Return on net worth margin, EPS,Earning Retention Ratios of Sun Pharma. So the Shareholder's Wealth will go up during pre and post-merger period.

Analysis of financial ratios of Torrent Pharma for Operating Performance

Table 3:- Analysis of financial ratios of Torrent Pharma for **Operating Performance**

Torrent Pharma		Mean	S.D	t-value	p-value
Operating Profit Margin	Pre	32.45	13.94	3.10	0.090
	Post	6.10	0.85		
Gross Profit Margin	Pre	22.56	4.56	-0.470	0.685
	Post	27.46	14.87		
Net Profit Margin	Pre	4.13	0.74	-3.736	0.65
	Post	22.85	7.96		
Return on Capital employed	Pre	35.53	14.57	0.424	0.713
	Post	28.77	18.01		
Debt-equity Ratio	Pre	0.53	0.11	-1.429	0.289
	Post	0.60	0.20		

Following the merger, the average operating profit margin and return on invested capital would fall from 32.45% to 6.10% and from 35.53% to 28.77%, respectively (t-value 3.10 and 0.424, respectively; 0.05% significance level; critical p-value 0.090 and 0.713, respectively; $p > 0.05$; therefore, not significant). However, the post-merger period saw an increase in the mean value of gross profit margin (from 22.56% to 27.46%), net profit margin (from 4.13% to 22.85%), and debt-equity ratio (from 0.53% to 0.60%), with t-values of respectively and P values of 0.685, 0.65, and 0.289, all of which are greater than 0.05% and thus insignificant. All three of these ratios have been on the rise after the merger, indicating improved operational performance. Therefore, we accept H0, which evaluates us to discover that the Gross profit margin, Net profit margin, and Debt-Equity Ratios of Tarrent Pharma are not significantly different pre- and post-merger. According to the results of the preceding research, Tarrent Pharma, the winning bidder, will see an improvement in Operating Performance as a result of the merger.

Table No-4:-Analysis of financial ratios of TorrentPharma for **Shareholder's wealth**

Torrent Pharma		Mean	S.D	t-value	p-value
	Pre	30.93	4.38		

Return onNet worth	Post	31.47	18.06	-0.046	0.967
Earnings Per Share(EPS)	Pre	28.03	13.19	-7.181	0.019
	Post	226.07	58.21		
Earning Retention Ratio	Pre	13.85	2.19	-12.278	0.052”
	Post	66.70	3.90		

Findings:

Improvement in Financial Ratios: The study reveals a positive trend in key financial ratios post-merger, indicating enhanced liquidity, profitability, and operational efficiency. Synergy Realization: Successful mergers resulted in effective synergy realization, leading to cost reductions, streamlined operations, and optimized resource utilization. Companies that efficiently integrated their operations experienced significant improvements in overall financial health.

Market Perception: Market reactions to the mergers were generally positive, with an initial increase in stock prices and trading volumes following the announcements. Positive market sentiment was observed when mergers were aligned with strategic objectives and effectively communicated to stakeholders.

Challenges in Integration: The study identified challenges related to post-merger integration, including cultural differences, organizational restructuring complexities, and technology assimilation hurdles. Companies that proactively addressed these challenges experienced smoother integration processes and better financial outcomes.

Suggestions:

Thorough Due Diligence: Conduct comprehensive due diligence before initiating mergers, focusing on financial, operational, legal, and cultural aspects.

Strategic Alignment: Ensure that the merger aligns with the long-term strategic goals of both companies. Mergers driven by complementary strengths and shared objectives are more likely to succeed and generate sustainable financial benefits.

Effective Communication: Transparent and timely communication with stakeholders, including employees, investors, and customers, is crucial. Clear communication about the merger's objectives, integration plans, and expected benefits fosters trust and confidence among stakeholders.

Proactive Integration Planning: Develop a robust integration plan addressing cultural integration, organizational restructuring, and technology assimilation. Proactive planning, involving cross-functional teams, can mitigate integration challenges and facilitate a smooth transition.

Continuous Monitoring: Implement a monitoring mechanism to track the progress of integration efforts and financial performance post-merger. Regular assessments will enable timely identification of issues, allowing for prompt corrective actions and adjustments to integration strategies.

Talent Retention: Retain key talent from both merging entities to ensure continuity and knowledge transfer. Developing retention programs and providing career development opportunities can enhance employee morale and reduce post-merger workforce disruptions.

Compliance and Regulatory Adherence: Stay vigilant about compliance requirements and adhere to regulatory standards throughout the merger process. Compliance failures can lead to legal complications and financial penalties, impacting the overall financial performance of the merged entity.

Continuous Improvement: Encourage a culture of continuous improvement within the merged organization. Foster innovation, invest in research and development, and explore new market opportunities to sustain growth and maintain a competitive edge in the pharmaceutical sector.

By incorporating these suggestions based on the study's findings, companies engaging in mergers within the Indian pharmaceutical sector can enhance their chances of successful integration and long-term financial prosperity.

Conclusion

The study of sector is essential for fostering a comprehensive understanding of the impact of mergers on companies' financial health. By exploring the financial nuances of selected mergers, this research contributes valuable knowledge to the existing literature, guiding future strategic decisions and promoting the overall growth and stability of the pharmaceutical industry in India. Post-merger, there is a noticeable improvement in key financial ratios, including liquidity, profitability, and efficiency metrics. Companies that successfully navigated the merger process experienced enhanced operational efficiency and increased profitability, indicating that well-executed mergers can contribute significantly to financial growth. The successful companies demonstrated effective synergy realization, leveraging the strengths of both merging entities to optimize resources and reduce operational costs. Strategic alignment, especially concerning product portfolios, research and development capabilities, and market presence, emerged as a critical factor. Mergers that aligned with long-term strategic goals exhibited superior financial outcomes, emphasizing the importance of strategic coherence in merger decisions. Challenges related to post-merger integration, such as cultural differences and organizational restructuring complexities, were identified. However, proactive integration planning and efficient communication strategies played pivotal roles in mitigating these challenges. Companies that invested in addressing integration hurdles experienced smoother transitions and quicker adaptation, minimizing disruptions to business operations. Positive market reactions were observed following merger announcements, reflecting investor confidence in the strategic rationale behind the mergers. Effective communication with stakeholders, including investors, employees, and customers, played a crucial role in shaping positive perceptions. Transparent communication regarding integration plans and expected benefits bolstered stakeholder confidence, underscoring the significance of communication strategies in managing market perceptions. Based on the findings, several recommendations are proposed for companies contemplating future mergers in the Indian pharmaceutical sector. Thorough due diligence, strategic alignment, effective communication, proactive integration planning, and continuous monitoring are pivotal for the success of mergers. Additionally, companies are encouraged to focus on talent retention, compliance adherence, and fostering a culture of continuous improvement to sustain growth and competitiveness post-merger. By highlighting factors that contribute to successful mergers and their subsequent impact on financial performance, this research equips industry stakeholders with actionable knowledge, enabling them to make informed decisions and navigate the complexities of M&A activities effectively. As the pharmaceutical sector continues to evolve, these findings serve as a foundation for future strategic initiatives, fostering sustainable growth and innovation within the industry.

References

1. Anup Agrawal Jeffrey F. Jaffe (1999), “The Post-mergerPerformance Puzzle”, Journal of Corporate Finance, USA.
2. Beena (2004), “Towards understanding the Merger Wave in the Indian Corporate Sector- A Comparative Perspective”, Working Paper, Centre for Development Studies, Thiruvananthapuram, India.
3. Ghosh and Dutta (2014),“Mergers and Acquisitions: A Strategic Tool for Restructuring in the Indian Telecom Sector”, Procedia Economics and Finance 11:396-409.
4. Kumar and Bansal (2008), “The impact of M&A on corporate performance in India”, Management Decision 46(10):1531-1543.
5. Dr.Naveen Prasadula (2021) Review of Literature on An Examination Of Financial Performance Before And After Mergers: A Case Study Of Selected Indian Pharmaceutical Companies
6. Mishra and Chandra (2010),” Mergers, Acquisitions and Firms Performance: Experience of Indian Pharmaceutical Industry”, Eurasian Journal of Business and Economics 2010, 3 (5), 111-126.
7. Neena Sinha, Dr. K.P.Kaushik & Ms. TimcyChaudhary, (2010), “Measuring Post Merger
8. andAcquisition Performance: An Investigation of SelectFinancial Sector Organizations in India”, InternationalJournal of Economics and Finance Vol. 2, No. 4; November2010.
9. N. M. Leepsa & Chandra Sekhar Mishra, (2012), “PostMerger Financial Performance: A Study with Reference toSelect Manufacturing Companies in India”, InternationalResearch Journal of Finance and Economics ISSN 1450-2887.
10. Pramod Mantravadi & A Vidyadhar Reddy (2008) “Post-Merger Performance of Acquiring Firms from DifferentIndustries in India”, International Research Journal ofFinance and Economics, ISSN 1450-2887.
11. Ramaswamy and Waegelein (2003),‘Firm Financial Performance Following Mergers’ Review of Quantitative Finance and Accounting, 2003, Volume 20, Number 2, Page 115.
12. Ramaswamy, K P and Waegelein, J F (2003), “FirmFinancial Performance Following Mergers,” Review ofQuantitative Finance and Accounting.
13. Salma Ahmed & Yasser Mahfooz (2009),“Consolidation in the Sky - A Case Study on the Quest

forSupremacy between Jetlite and Kingfisher Airlines"Working paper series Aligarh Muslim University.
14. Saple (2000), "Diversification, Mergers and their Effect onFirm Performance: A Study of the Indian Corporate Sector",Unpublished Ph.D. thesis submitted to IGIDR, Mumbai.
15. Vardhana Pawaskar, (2001), "Effect of Mergers on Corporate Performance in India ", The Journal for Decision Makers, Vol. 26(4).
16. Vulanovic (2017),"Determinants of mergers: a case of specified purpose acquisition companies (SPACs)", Investment Management and Financial Innovations.
17. Yeh and Hoshin(2002)," Productivity and operating performance of Japanese merging firms: Keiretsurelated and independent mergers", Japan and the World Economy, vol. 14, issue 3, 347-366.